Cargando…

Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review

Oxaliplatin-based chemotherapy is extensively used for the treatment of gastrointestinal tumors and other malignancies. Oxaliplatin-related hypersensitivity reactions (HSRs) are common during antitumor treatment. Several studies have been conducted to identify predictive risk factors for oxaliplatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbin, Francesca, Ghidini, Michele, Panichi, Alessandra, Tomasello, Gianluca, Bareggi, Claudia, Galassi, Barbara, Denaro, Nerina, Ruatta, Fiorella, Cauchi, Carolina, Rossino, Maria Grazia, Garrone, Ornella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775529/
https://www.ncbi.nlm.nih.gov/pubmed/36552030
http://dx.doi.org/10.3390/biomedicines10123275
_version_ 1784855666771361792
author Barbin, Francesca
Ghidini, Michele
Panichi, Alessandra
Tomasello, Gianluca
Bareggi, Claudia
Galassi, Barbara
Denaro, Nerina
Ruatta, Fiorella
Cauchi, Carolina
Rossino, Maria Grazia
Garrone, Ornella
author_facet Barbin, Francesca
Ghidini, Michele
Panichi, Alessandra
Tomasello, Gianluca
Bareggi, Claudia
Galassi, Barbara
Denaro, Nerina
Ruatta, Fiorella
Cauchi, Carolina
Rossino, Maria Grazia
Garrone, Ornella
author_sort Barbin, Francesca
collection PubMed
description Oxaliplatin-based chemotherapy is extensively used for the treatment of gastrointestinal tumors and other malignancies. Oxaliplatin-related hypersensitivity reactions (HSRs) are common during antitumor treatment. Several studies have been conducted to identify predictive risk factors for oxaliplatin-related HSRs, but findings remain controversial. No definitive approach has been identified to reduce the risk of developing HSRs. The aim of this article is to provide an overview of oxaliplatin-related HSRs, and to report our institution’s experience. With our work, we reviewed available data from the literature and described our case series. A total of 153 patients were treated with oxaliplatin and 17 developed an HSR. On the whole, 70.6% of reactions were Grade 3, mostly with respiratory and cutaneous symptoms. Steroids and antihistamines were administered to reduce hypersensitivity symptoms and prevent further reactions. A stronger premedication and prolonged time of infusion resulted in milder reactions or absence of subsequent reactions. We did not find any clear predictive factor for the development of HSRs. Although it is not possible to cancel the risk of oxaliplatin-based HSRs, strategies to reduce the risk of occurrence could be stronger premedication and prolonged time of infusion.
format Online
Article
Text
id pubmed-9775529
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97755292022-12-23 Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review Barbin, Francesca Ghidini, Michele Panichi, Alessandra Tomasello, Gianluca Bareggi, Claudia Galassi, Barbara Denaro, Nerina Ruatta, Fiorella Cauchi, Carolina Rossino, Maria Grazia Garrone, Ornella Biomedicines Article Oxaliplatin-based chemotherapy is extensively used for the treatment of gastrointestinal tumors and other malignancies. Oxaliplatin-related hypersensitivity reactions (HSRs) are common during antitumor treatment. Several studies have been conducted to identify predictive risk factors for oxaliplatin-related HSRs, but findings remain controversial. No definitive approach has been identified to reduce the risk of developing HSRs. The aim of this article is to provide an overview of oxaliplatin-related HSRs, and to report our institution’s experience. With our work, we reviewed available data from the literature and described our case series. A total of 153 patients were treated with oxaliplatin and 17 developed an HSR. On the whole, 70.6% of reactions were Grade 3, mostly with respiratory and cutaneous symptoms. Steroids and antihistamines were administered to reduce hypersensitivity symptoms and prevent further reactions. A stronger premedication and prolonged time of infusion resulted in milder reactions or absence of subsequent reactions. We did not find any clear predictive factor for the development of HSRs. Although it is not possible to cancel the risk of oxaliplatin-based HSRs, strategies to reduce the risk of occurrence could be stronger premedication and prolonged time of infusion. MDPI 2022-12-17 /pmc/articles/PMC9775529/ /pubmed/36552030 http://dx.doi.org/10.3390/biomedicines10123275 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Barbin, Francesca
Ghidini, Michele
Panichi, Alessandra
Tomasello, Gianluca
Bareggi, Claudia
Galassi, Barbara
Denaro, Nerina
Ruatta, Fiorella
Cauchi, Carolina
Rossino, Maria Grazia
Garrone, Ornella
Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review
title Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review
title_full Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review
title_fullStr Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review
title_full_unstemmed Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review
title_short Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review
title_sort oxaliplatin-related hypersensitivity reactions: a single institution series and literature review
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775529/
https://www.ncbi.nlm.nih.gov/pubmed/36552030
http://dx.doi.org/10.3390/biomedicines10123275
work_keys_str_mv AT barbinfrancesca oxaliplatinrelatedhypersensitivityreactionsasingleinstitutionseriesandliteraturereview
AT ghidinimichele oxaliplatinrelatedhypersensitivityreactionsasingleinstitutionseriesandliteraturereview
AT panichialessandra oxaliplatinrelatedhypersensitivityreactionsasingleinstitutionseriesandliteraturereview
AT tomasellogianluca oxaliplatinrelatedhypersensitivityreactionsasingleinstitutionseriesandliteraturereview
AT bareggiclaudia oxaliplatinrelatedhypersensitivityreactionsasingleinstitutionseriesandliteraturereview
AT galassibarbara oxaliplatinrelatedhypersensitivityreactionsasingleinstitutionseriesandliteraturereview
AT denaronerina oxaliplatinrelatedhypersensitivityreactionsasingleinstitutionseriesandliteraturereview
AT ruattafiorella oxaliplatinrelatedhypersensitivityreactionsasingleinstitutionseriesandliteraturereview
AT cauchicarolina oxaliplatinrelatedhypersensitivityreactionsasingleinstitutionseriesandliteraturereview
AT rossinomariagrazia oxaliplatinrelatedhypersensitivityreactionsasingleinstitutionseriesandliteraturereview
AT garroneornella oxaliplatinrelatedhypersensitivityreactionsasingleinstitutionseriesandliteraturereview